Literature DB >> 3620296

Drug interaction between propafenone and metoprolol.

F Wagner, D Kalusche, D Trenk, E Jähnchen, H Roskamm.   

Abstract

1 The steady-state plasma concentrations of metoprolol and propafenone were determined in patients being treated with one of these drugs alone and during combined treatment with both drugs. In addition, single dose studies with metoprolol, propafenone and the combination of both drugs were performed in healthy volunteers to determine the pharmacokinetics and the time course of beta-adrenoceptor blocking activity. 2 In four patients being treated with metoprolol first and subsequently with propafenone in addition steady-state levels of metoprolol increased two to five fold with simultaneous treatment with propafenone. 3 In four patients being treated with the drug combination first and thereafter with propafenone alone no changes in the steady-state levels of propafenone were observed between both treatment periods. 4 Adverse effects of the drug combination were observed in two patients (one patient experienced severe nightmares and the other left ventricular failure). 5 When single oral doses of metoprolol (50 mg) and propafenone (150 mg) and the combination of both were administered to healthy subjects, an approximately two-fold decrease of the oral clearance of metoprolol was seen when propafenone was given in addition. No conclusive changes in the pharmacokinetics of propafenone could be detected in the presence of metoprolol. 6 Duration of beta-adrenoceptor blocking activity of a single dose of metoprolol in healthy volunteers as measured by reduction of exercise-induced tachycardia increased when propafenone was given in addition. 7 The dose of metoprolol should be reduced when propafenone is given in addition.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3620296      PMCID: PMC1387752          DOI: 10.1111/j.1365-2125.1987.tb03164.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  The effects of a cardioselective (metoprolol) and a nonselective (propranolol) beta-adrenergic blocker on the response to dynamic exercise in normal men.

Authors:  J Sklar; G D Johnston; P Overlie; J G Gerber; H L Brammell; J Gal; A S Nies
Journal:  Circulation       Date:  1982-05       Impact factor: 29.690

Review 2.  Clinical pharmacokinetics of metoprolol.

Authors:  C G Regårdh; G Johnsson
Journal:  Clin Pharmacokinet       Date:  1980 Nov-Dec       Impact factor: 6.447

3.  Clinical pharmacology of propafenone.

Authors:  S J Connolly; R E Kates; C S Lebsack; D C Harrison; R A Winkle
Journal:  Circulation       Date:  1983-09       Impact factor: 29.690

4.  The metabolic fate of 2H-labelled propafenone in man.

Authors:  H G Hege; M Hollmann; S Kaumeier; H Lietz
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jan-Mar       Impact factor: 2.441

5.  Metabolite cumulation during chronic propafenone dosing in arrhythmia.

Authors:  R E Kates; Y G Yee; R A Winkle
Journal:  Clin Pharmacol Ther       Date:  1985-06       Impact factor: 6.875

6.  Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine.

Authors:  R H Briant; R E Dorrington; D G Ferry; J W Paxton
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Investigations on the pharmacokinetics of propafenone in man.

Authors:  M Hollmann; E Brode; D Hotz; S Kaumeier; O H Kehrhahn
Journal:  Arzneimittelforschung       Date:  1983

8.  Propafenone disposition kinetics in cardiac arrhythmia.

Authors:  S Connolly; C Lebsack; R A Winkle; D C Harrison; R E Kates
Journal:  Clin Pharmacol Ther       Date:  1984-08       Impact factor: 6.875

9.  Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations.

Authors:  L A Siddoway; D M Roden; R L Woosley
Journal:  Am J Cardiol       Date:  1984-11-14       Impact factor: 2.778

  9 in total
  18 in total

Review 1.  beta-blockers. Drug interactions of clinical significance.

Authors:  I Blaufarb; T M Pfeifer; W H Frishman
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

Review 2.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

3.  Transfer of propafenone and 5-OH-propafenone to foetal plasma and maternal milk.

Authors:  M Libardoni; D Piovan; E Busato; R Padrini
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

4.  Clinically important interaction between metoprolol and propafenone.

Authors:  Jana Duricova; Ilona Perinova; Nikola Jurckova; Ivana Kacirova; Milan Grundmann
Journal:  Can Fam Physician       Date:  2013-04       Impact factor: 3.275

5.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 6.  Genetically determined adverse drug reactions involving metabolism.

Authors:  M S Lennard
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

Review 7.  Clinical significance of genetic influences on cardiovascular drug metabolism.

Authors:  L Arcavi; N L Benowitz
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

Review 8.  Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Authors:  Nina Isoherranen; Justin D Lutz; Sophie P Chung; Houda Hachad; Rene H Levy; Isabelle Ragueneau-Majlessi
Journal:  Chem Res Toxicol       Date:  2012-09-27       Impact factor: 3.739

Review 9.  Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Authors:  H M Bryson; K J Palmer; H D Langtry; A Fitton
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 10.  Omeprazole drug interaction studies.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.